Country: United States
Language: English
Source: NLM (National Library of Medicine)
CROMOLYN SODIUM (UNII: Q2WXR1I0PK) (CROMOLYN - UNII:Y0TK0FS77W)
Woodward Pharma Services LLC
CROMOLYN SODIUM
CROMOLYN SODIUM 20 mg in 2 mL
INTRABRONCHIAL
PRESCRIPTION DRUG
Cromolyn sodium inhalation solution USP is a prophylactic agent indicated in the management of patients with bronchial asthma. In patients whose symptoms are sufficiently frequent to require a continuous program of medication, cromolyn sodium inhalation solution USP is given by inhalation on a regular daily basis (see DOSAGE AND ADMINISTRATION ). The effect of cromolyn sodium is usually evident after several weeks of treatment, although some patients show an almost immediate response. In patients who develop acute bronchoconstriction in response to exposure to exercise, toluene diisocyanate, environmental pollutants, etc., cromolyn sodium should be given shortly before exposure to the precipitating factor (see DOSAGE AND ADMINISTRATION ). Cromolyn sodium inhalation solution is contraindicated in those patients who have shown hypersensitivity to cromolyn sodium.
Cromolyn Sodium Inhalation Solution USP Unit-Dose 2 mL Vial is supplied as a colorless to pale yellow solution containing 20 mg cromolyn sodium, USP, in water for injection, USP, with 30 vials per foil pouch in a carton as listed below. 60 vials per carton (NDC 70556-102-60). Each vial is made from a low density polyethylene (LDPE) resin. Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Do not use if solution is discolored or contains a precipitate. Retain in foil pouch until time of use. PROTECT FROM LIGHT. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. Marketed by: Woodward Pharma Services LLC Birmingham, MI 48009
Abbreviated New Drug Application
CROMOLYN SODIUM- CROMOLYN SODIUM SOLUTION WOODWARD PHARMA SERVICES LLC ---------- CROMOLYN SODIUM INHALATION SOLUTION, USP PRESCRIBING INFORMATION RX ONLY FOR ORAL INHALATION USE ONLY - NOT FOR INJECTION DESCRIPTION The active ingredient of cromolyn sodium inhalation solution USP is cromolyn sodium, USP. It is an inhaled anti-inflammatory agent for the preventive management of asthma. Cromolyn sodium, USP is chemically designated as disodium 5,5'- [(2- hydroxytrimethylene)dioxy] bis [4-oxo-4_H_-1-benzopyran-2-carboxylate]. The molecular formula is C H Na O ; the molecular weight is 512.34. Cromolyn sodium, USP is a water-soluble, odorless, white, hydrated crystalline powder. It is tasteless at first, but leaves a slightly bitter aftertaste. Cromolyn sodium inhalation solution USP is clear, colorless to pale yellow, sterile and has a target pH of 5.5. The structural formula is: Each 2 mL vial for oral inhalation use only contains 20 mg cromolyn sodium, USP in water for injection, USP. CLINICAL PHARMACOLOGY _In vitro_ and _in vivo_ animal studies have shown that cromolyn sodium inhibits sensitized mast cell degranulation which occurs after exposure to specific antigens. Cromolyn sodium acts by inhibiting the release of mediators from mast cells. Studies show that cromolyn sodium indirectly blocks calcium ions from entering the mast cell, thereby preventing mediator release. Cromolyn sodium inhibits both the immediate and non-immediate bronchoconstrictive reactions to inhaled antigen. Cromolyn sodium also attenuates bronchospasm caused by exercise, toluene diisocyanate, aspirin, cold air, sulfur dioxide, and environmental 23 14 2 11 pollutants. Cromolyn sodium has no intrinsic bronchodilator or antihistamine activity. After administration by inhalation, approximately 8% of the total cromolyn sodium dose administered is absorbed and rapidly excreted unchanged, approximately equally divided between urine and bile. The remainder of the dose is either exhaled or deposited in the oropharynx, swallowed and excreted via th Read the complete document